

Original Article

**FORMULATION AND EVALUATION OF CAPECITABINE LOADED NANO PARTICLES**

Dr. G. Nagaraju<sup>1\*</sup>, Lavdya Teena<sup>2</sup>, V. Sirisha<sup>3</sup>, Dr. Hareesh Dara<sup>1</sup>.

<sup>1\*</sup> Department of Pharmaceutical Chemistry, Dhanvanthari Institute of Pharmaceutical, Sciences, Sujathanagar, Kothagudem.

<sup>1,2</sup> Department of Pharmaceutics, Sree College of Pharmacy, nayakulagudem, Kothagudem, Telangana.

<sup>3</sup> Department of Pharmaceutics, Dhanvanthari Institute of Pharmaceutica Sciences, Sujathanagar, Kothagudem.

Received on: 15-11-2023

Revised and Accepted on: 31-12-2023

**ABSTRACT**

*Nano particles represent a promising drug delivery system of controlled and targeted drug release. They are specially designed to release the drug in the vicinity of target tissue. The aim of this study was to prepare and evaluate polymethacrylic acid nanoparticles containing Capecitabine in different drug to polymer ratio by nano precipitation method. SEM indicated that nanoparticles have a discrete spherical structure without aggregation. The average particle size was found to be 121 ± 8 - 403 ± 4 nm. The particle size of the nanoparticles was gradually increased with increase in the proportion of polymethacrylic acid polymer. The drug content of the nanoparticles was increasing on increasing polymer concentration up to a particular concentration. No appreciable difference was observed in the extent of degradation of product during 60 days in which, nanoparticles were stored at various temperatures. FT-IR studies indicated that there was no chemical interaction between drug and polymer and stability of drug. The in-vitro release behavior from all the drug loaded batches was found to be zero order and provided sustained release over a period of 24h. The developed formulation overcome and alleviates the drawbacks and limitations of Capecitabine sustained release formulations and could possibly be advantageous in terms of increased bioavailability of Capecitabine.*

**KEYWORDS:**-Nanoparticles, Capecitabine, biodegradable, polymethacrylic acid

**INTRODUCTION**

During last two decades, considerable attention has been given to the development of novel drug delivery system (NDDS) <sup>1</sup>. The rationale for control drug delivery is to alter the pharmacokinetics and pharmacodynamics of drug substance in order to improve the therapeutic efficacy and safety through the use of novel drug delivery system. Besides more traditional matrix or reservoir drug delivery system, colloidal drug delivery system has gained in popularity. The major colloidal drug delivery system includes liposome and polymeric nanoparticles. Theses systems have been investigated primarily for site specific drug delivery, for controlled drug delivery, and also for the

enhancement of dissolution rate/bioavailability of poorly water-soluble drugs. The primary routes of administration under investigation are parenteral route; however, other routes such as the oral, ocular, or topical routes are also being investigated. In era of oral drug delivery system microspheres<sup>2</sup>, microcapsule, nanoparticles, liposomes, and niosomes are better options to conventional dosage form. Nanoparticles are colloidal polymer particles of a size below 1µm<sup>3-4</sup> and hold promise as drug delivery for parenteral, peroral and ocular administration as well as adjuvant for vaccines. Due to their greater stability and due to their easier manufacturing they offer advantages over other colloidal carriers such as liposomes and cell ghosts. They offer advantages like increased bioavailability, site specific drug delivery, sustained release of drug over longer period of time, retention of dosage form in entire length of gastrointestinal tract and convenient to patient due to reduction in frequent dosing <sup>5</sup>.

Eudragit polymers are series of acrylate and methacrylate polymer available in different ionic forms. Eudragit RS 100 is insoluble in aqueous media but it is permeable and has pH-independent release profile. The permeability of Eudragit RS 100 is due to presence of quaternary ammonium group in their

**\*Corresponding author:**

**Dr. G. Nagaraju**

Department of Pharmaceutical Chemistry, Dhanvanthari  
Institute of Pharmaceutical Sciences, Sujathanagar, Kothagudem.

Email: [gdp413@gmail.com](mailto:gdp413@gmail.com)

DOI: <https://doi.org/10.5281/zenodo.14235266>

structure<sup>6</sup>. Capecitabine is a potent antiviral agent used in the treatment of AIDS.

Conventional oral formulations Capecitabine are administered multiple times a day (150 mg twice daily) because of its moderate half-life (5-7 hours)<sup>7-8</sup>. Treatment of AIDS using conventional formulations of Capecitabine is found to have many draw backs, such as adverse side effects resulting from accumulation of drug in multidose therapy, poor patient compliance, and high cost. The objective of the present study was to prepare nanoparticles of Capecitabine to overcome some of these problems.

#### MATERIAL AND METHOD:

Capecitabine was a gift sample from Ajantha pharma. Eudragit RS 100 was obtained from Rohm Pharma, Germany. Dichloromethane was procured from E. Merck Ltd., Mumbai. All other chemicals used were of analytical grade.

#### Preparation of nanoparticles

Nanoparticles containing Capecitabine were prepared using nano precipitation method<sup>9-10</sup>. Drug was dissolved in water, and then co-solvent (acetone) was added into this solution. A co-solvent was needed in order to make the inner phase more homogeneous. Then polymer and 150 mg of propylene glycol were dissolved in chloroform, and this solution was added to the drug solution to form dispersion. The dispersion was added to 10 ml of aqueous ethanol solution (70%). After 5 minutes of mixing, the organic solvents were removed by evaporation at 35° under normal pressure, nano particles were separated by using cooling centrifuge (10000 rpm for 20 min), supernatant were removed and nanoparticles washed with water and dried at room temperature in a desicator. By following the above mentioned procedure five other batches of nanoparticles ratio of 1:1, 1:2, 1:3, 1:4 and 1:5 were prepared and named F1, F2, F3, F4 and F5 respectively.

Particle size, surface morphology and zeta potential. The surface morphology (roundness, smoothness, and formation of aggregates) and particle size were studied by scanning electron microscopy (SEM)<sup>11,12</sup>. Zeta potential of the best formulation (F4) was determined by zeta potential probe model DT-300.

#### Drug Content

Drug content was determined by centrifugation method. The redispersed nanoparticles suspension was centrifuged at 15,000 rpm for 40 min at 25° to separate the free drug in the supernatant. Concentration of Capecitabine in the supernatant was determined by UV-Visspectrophotometry at 271nm after suitable dilution. Fourier Transform Infra-red Spectroscopy (FT-IR) analysis

The FT-IR spectra of pure Capecitabine and Eudragit RS 100 nanoparticles loaded with Capecitabine were recorded to check drug polymer interaction and stability of drug. In vitro release studies In-vitro release studies were carried out by using dialysis

tubes with an artificial membrane. The prepared Capecitabine nanoparticles and 10 ml of phosphate buffer pH 7.4 was added to the dialysis tube and subjected to dialysis by immersing the dialysis tube to the receptor compartment containing 250 ml of phosphate buffer pH 6.8. The medium in the receptor was agitated continuously using a magnetic stirrer a temperature was maintained at 37±1°. 5ml of sample of receptor compartment were taken at various interval softime over a period of 24 hand each time fresh buffer was replaced. The amount of drug released was determined spectrometrically at 271nm.

#### Kinetic modeling

In order to understand the kinetic and mechanism of drug release, the result of in vitro drug release study of nanoparticles were fitted with various kinetic equation like zero order<sup>13</sup> (cumulative % release vs. time), first order<sup>14</sup> (log % drug remaining vs time), Higuchi's model<sup>15</sup> (cumulative % drug release vs. square root of time). r<sup>2</sup> and k values were calculated for the linear curve obtained by regression analysis of the above plots.

#### Stability study:

The stability study was carried using the batch F4. The stability of drug loaded nanoparticles was evaluated in terms of its drug content<sup>16</sup>. The stability of nanoparticles was evaluated in PBS (pH 6.8). Nanoparticles formulation was incubated at 5-8° and 37 ± 1° for a period of 60 d. After specified time intervals, the suspension was centrifuged at 15,000 rpm for 1 h, supernatant was removed and nanoparticles were dissolved in dichloromethane. After adding of water and separation, the amount of drug was detected by UV-Visspectrophotometrically method at 271nm.

#### RESULT AND DISCUSSION

Capecitabine nano particles with varying proportions of Capecitabine and Eudragit RS 100 were prepared by nanoprecipitation method. The scanning electron micro photograph of Capecitabine nanoparticles is shown in fig.1. It indicated that Capecitabine nanoparticles have a discrete spherical structure without aggregation. The particle size of nanoparticles varied somewhat among the formulation due to variation in the composition of formulations. Zeta potential of best formulation was determined and it was found +27mV due to quaternary ammonium group of Eudragit. Since there was a decrease of surface potential, it could be concluded that a part of drug was absorbed on the polymeric particles.

The drug content was determined by centrifugation method and it was maximum in formulation FN4. The nanoparticles exhibited an increase in drug content with an increased in the polymer ratio, up to particular concentration (1:4). A decrease in drug content was observed after that point due to the saturation capacity of polymer. In FT-IR study the characteristic peak due to pure Capecitabine has appeared in the spectra of nanoparticles

without any markable change in the position. It indicated that there was no chemical interaction between Capecitabine and Eudragit RS 100. Instability study there was no remarkable change in the drug content. This indicated that formulation was stable in storage medium condition. The in vitro release profile of all formulation is shown in fig.2. The release of Capecitabine mainly depended upon the polymer concentration. The burst release of Capecitabine from nano particles at initial stage resulted from the dissolution of drug crystals on the surface of nanoparticles. On increasing polymer concentration, the release rate of Capecitabine from nanoparticles decreased drastically. The in vitro release data was applied to various kinetic models to predict the drug release kinetic mechanism. The release constant was calculated from the slope of appropriate plots, and the regression coefficient ( $r^2$ ) was determined. It was found that the in-vitro drug release of nano particles was best explained by zero order kinetics for best formulation F4 as the plots shows highest linearity. The correlation coefficient ( $r^2$ ) was found 0.99 for F4.


### CONCLUSION

The method of preparation of nanoparticles of Capecitabine was found to be simple and reproducible. The slow and constant release of Capecitabine from nanoparticles maintain constant drug plasma concentration thereby increasing therapeutic efficacy. This study shows that polymethacrylic acid nanoparticles could be a useful carrier for Capecitabine. The developed formulation overcome and all eviates the drawbacks and limitations of Capecitabine sustained release formulations.

**Table 1: Formulation and physicochemical characterization of Capecitabine nanoparticles**

Formulation code	Drug: Polymer ratio	Drug Content* (%)	Particle Size* (nm)
FN <sub>1</sub>	1:1	58.32 ± 0.02	121 ± 8
FN <sub>2</sub>	1:2	64.13 ± 0.08	265 ± 5
FN <sub>3</sub>	1:3	70.83 ± 0.03	287 ± 9
FN <sub>4</sub>	1:4	64.62 ± 0.02	332 ± 5
FN <sub>5</sub>	1:5	59.96 ± 0.04	403 ± 4


\*Average of three preparation ± S.D




A.

B.

**Fig.1: Scanning electron microphotograph of Capecitabine nanoparticles (A) At lower magnification (B) At higher magnification**



**Fig. 2: FTIR spectra of pure Capecitabine and Capecitabine loaded nano particles formulation (FN4)**



**Fig. 3: In-vitro drug release of Capecitabine from poly methacrylic acid nano particles formulation**

## REFERENCES

1. Santhi K., Dhanraj S. A., Nagasamy Venkatesh D., Sangeetha S., Suresh B., Preparation and optimization of sodium alginate nanospheres of methotrexate, *Indian J. Pharm. Sci.*, 2005, 67, 691- 696.
2. Tamizharasi S., Rathi J. C., Rathi V., Formulation, characterization and in vitro release kinetic of aceclofenac loaded poly( $\epsilon$ -caprolactone) microspheres, *Indian Drugs*, 2007, 44, 973-975.
3. Kreuter J., Nanoparticles based drug delivery systems, *J. Control. Rel.*, 1991, 16, 169-176.
4. Bandameedi R., Pandiyan P. S. Formulation and evaluation of gastroretentive floating bioadhesive tablets of hydrochlorothiazide. *Asian J Pharm Clin Res* 2017; 10:150-5.
5. Chen D. B., Yang T. Z., Lu W. L., Zhang Q., In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing paclitaxel, *Chem. Pharm. Bull.*, 2001, 49, 1444-1447.
6. Ubrich N., Schmidt C., Bodmeur R., Hoffman M., Maincent P., Oral evaluation in rabbits of cyclosporin loaded Eudragit RSor RL nanoparticles, *Int. J. Pharm.*, 2005, 288, 169-175.
7. Punna R. R., Sindhura G., Saha R. N., Design and Study of Capecitabine Oral Controlled Release Tablet, *AAPS Pharm Sci Tech*, 2007, 8, E1-E9.
8. Saibaba, S. V.; Kumar, M. S.; Ramu, B. Pharmaceutical impurities and their characterization. *European J Pharm Med Res* 2016, 3(5), 190-196.
9. Leena Peltonen., The Effect of Cosolvents on the Formulation of Nanoparticles From Low-Molecular-Weight Poly(l)lactide *AAPS Pharm Sci Tech.*, 2002, 3, E1-E7.
10. Barbault S., Gref R., Russo P., Guehot J., Bochot A., Design of poly- $\epsilon$ -caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery, *J. Control. Rel.*, 2002, 83, 365-375.
11. Peltonen L., Koistinen P., Karjalainen M., Hakkinen A., Hirvonen J., The effect of cosolvents on the formulation of nanoparticles from low molecular weight poly(l)lactide, *AAPS Pharm Sci Tech*, 2002, 3, 1-7.
12. Cui F., Oian F., Yin C., Preparation and characterization of muco adhesive polymer-coated nanoparticles, *Int. J. Pharm.*, 2006, 316, 154- 161.
13. Saparia B., Murthy R. S. R., Solanki A., Preparation and evaluation of chloroquine phosphate microspheres using cross-linked gelatin for long term drug delivery, *Indian J. Pharm. Sci.*, 2002, 64, 48-52.
14. Haznedar S., Dortunc B., Preparation and evaluation of Eudragit microspheres containing acetazolamide, *Int. J. Pharm.*, 2004, 269, 131-140.
15. Higuchi T., Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices, *J. Pharm. Sci.*, 1963, 52, 1145-1149.
16. Ramteke S., Maheshwari R. B. V., Jain N. K., Clarithromycin based oral sustained release nanoparticulate drug delivery system, *Indian J. Pharm. Sci.*, 2006, 68, 479-484.
17. Chowdary K. P. R., Rao Y. S., Mucoadhesive microcapsules of glipizide: Characterization, in vitro and in vivo evaluation, *Indian J. Pharm. Sci.*, 2006, 68, 479-484.
18. Chowdary K. P. R., Rao N. K., Malathi K., Ethylcellulose microsphere of glipizide: Characterization, in vitro and in vivo evaluation, *Indian J. Pharm. Sci.*, 2004, 66, 412-416.

**How to cite this article:**

Dr. G. Nagaraju\*, FORMULATION AND EVALUATION OF CAPECITABINE LOADED NANO PARTICLES *J Pharm Res*, 2023; 12(06): 70-73. DOI: <https://doi.org/10.5281/zenodo.14235266>

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Source of support:** Nil